Recent study has revealed that CBX2 was significantly upregulated in breast cancer and prostate cancer and may serve as a prognostic biomarker.8, 9, 10 Consistent with this previous study, our study confirmed the dramatically upregulated CBX2 in osteosarcoma and high CBX2 expression was correlated with metastasis, recurrence, and chemotherapy response, as well as unfavorable prognosis in patients with osteosarcoma. Here, CBX2 is linked to prostate carcinoma.